These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 30048367)

  • 21. Nonalcoholic fatty liver disease as a sentinel marker for the development of diabetes mellitus in non-obese subjects.
    Kim SS; Cho HJ; Kim HJ; Kang DR; Berry JR; Kim JH; Yang MJ; Lim SG; Kim S; Cheong JY; Cho SW
    Dig Liver Dis; 2018 Apr; 50(4):370-377. PubMed ID: 29398414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonalcoholic Fatty Liver Disease: A Unique Entity or Part of the Metabolic Syndrome or Both.
    Yip TC; Wong GL; Wong VW; Goh GB; Chan WK
    Med Clin North Am; 2023 May; 107(3):449-463. PubMed ID: 37001947
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: a brief review.
    Borém LMA; Neto JFR; Brandi IV; Lelis DF; Santos SHS
    Hypertens Res; 2018 Jun; 41(6):394-405. PubMed ID: 29636553
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes.
    Karalliedde J; Viberti G
    J Hum Hypertens; 2006 Apr; 20(4):239-53. PubMed ID: 16452996
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nonalcoholic Fatty Liver Disease and Metabolic Syndrome.
    Kim D; Touros A; Kim WR
    Clin Liver Dis; 2018 Feb; 22(1):133-140. PubMed ID: 29128053
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renin-angiotensin-aldosterone system blockade effects on the kidney in the elderly: benefits and limitations.
    Turgut F; Balogun RA; Abdel-Rahman EM
    Clin J Am Soc Nephrol; 2010 Jul; 5(7):1330-9. PubMed ID: 20498247
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Obesity, essential hypertension and renin-angiotensin system.
    Segura J; Ruilope LM
    Public Health Nutr; 2007 Oct; 10(10A):1151-5. PubMed ID: 17903324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-alcoholic fatty liver disease and its associations among adolescents in an urban, Sri Lankan community.
    Rajindrajith S; Pathmeswaran A; Jayasinghe C; Kottahachchi D; Kasturiratne A; de Silva ST; Niriella MA; Dassanayake AS; de Silva AP; de Silva HJ
    BMC Gastroenterol; 2017 Nov; 17(1):135. PubMed ID: 29187144
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Prevention of type 2 diabetes mellitus due to antihypertensive treatment affecting renin-angiotensin system].
    Boucek P
    Vnitr Lek; 2006 Sep; 52(9):791-6. PubMed ID: 17091602
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonalcoholic fatty liver disease: Evolving paradigms.
    Lonardo A; Nascimbeni F; Maurantonio M; Marrazzo A; Rinaldi L; Adinolfi LE
    World J Gastroenterol; 2017 Sep; 23(36):6571-6592. PubMed ID: 29085206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of Psoriasis With Comorbidity Development in Children With Psoriasis.
    Tollefson MM; Van Houten HK; Asante D; Yao X; Maradit Kremers H
    JAMA Dermatol; 2018 Mar; 154(3):286-292. PubMed ID: 29322175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Research advances in the impact of nonalcoholic fatty liver disease on cardiac structure and function].
    Gu LF; Wang YQ; Fan JG
    Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):461-4. PubMed ID: 27465954
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reporting of the estimated glomerular filtration rate was associated with increased use of angiotensin-converting enzyme inhibitors and angiotensin-II receptor blockers in CKD.
    Jain AK; Cuerden MS; McLeod I; Hemmelgarn B; Akbari A; Tonelli M; Quinn RR; Oliver MJ; Garg AX
    Kidney Int; 2012 Jun; 81(12):1248-53. PubMed ID: 22437415
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms.
    Saponaro C; Gaggini M; Gastaldelli A
    Curr Diab Rep; 2015 Jun; 15(6):607. PubMed ID: 25894944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.
    Talbert RL
    J Am Pharm Assoc (2003); 2010; 50(5):e116-25. PubMed ID: 20833609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiotensin receptor blockers: novel role in high-risk patients.
    Javed U; Deedwania PC
    Cardiol Clin; 2008 Nov; 26(4):507-26. PubMed ID: 18929228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of and predictive factors for nonalcoholic fatty liver disease in Sudanese individuals with type 2 diabetes: Is metabolic syndrome the culprit?
    Almobarak AO; Barakat S; Suliman EA; Elmadhoun WM; Mohamed NA; Abobaker IO; Noor SK; Bushara SO; Ahmed MH
    Arab J Gastroenterol; 2015 Jun; 16(2):54-8. PubMed ID: 26174761
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease.
    Pelusi S; Petta S; Rosso C; Borroni V; Fracanzani AL; Dongiovanni P; Craxi A; Bugianesi E; Fargion S; Valenti L
    PLoS One; 2016; 11(9):e0163069. PubMed ID: 27649410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Psoriasis and Nonalcoholic Fatty Liver Disease.
    Carrascosa JM; Bonanad C; Dauden E; Botella R; Olveira-Martín A;
    Actas Dermosifiliogr; 2017; 108(6):506-514. PubMed ID: 28318525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.